Cargando…

Evaluation of Endocrine Late Complications in Childhood Acute Lymphoblastic Leukemia Survivors: A Report of a Single-Center Experience and Review of the Literature

OBJECTIVE: Improvement in long-term survival in patients with acute lymphoblastic leukemia (ALL) in childhood has led to the need for monitorization of treatment-related morbidity and mortality. In the current study, we aimed to evaluate endocrine side effects of treatment in ALL survivors who were...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayram, Cengiz, Yaralı, Neşe, Fettah, Ali, Demirel, Fatma, Tavil, Betül, Kara, Abdurrahman, Tunç, Bahattin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451687/
https://www.ncbi.nlm.nih.gov/pubmed/27094350
http://dx.doi.org/10.4274/tjh.2015.0332
_version_ 1783240223562399744
author Bayram, Cengiz
Yaralı, Neşe
Fettah, Ali
Demirel, Fatma
Tavil, Betül
Kara, Abdurrahman
Tunç, Bahattin
author_facet Bayram, Cengiz
Yaralı, Neşe
Fettah, Ali
Demirel, Fatma
Tavil, Betül
Kara, Abdurrahman
Tunç, Bahattin
author_sort Bayram, Cengiz
collection PubMed
description OBJECTIVE: Improvement in long-term survival in patients with acute lymphoblastic leukemia (ALL) in childhood has led to the need for monitorization of treatment-related morbidity and mortality. In the current study, we aimed to evaluate endocrine side effects of treatment in ALL survivors who were in remission for at least 2 years. MATERIALS AND METHODS: Sixty patients diagnosed with ALL, who were in remission for at least 2 years, were cross-sectionally evaluated for long-term endocrine complications. RESULTS: The median age of the patients at the time of diagnosis, at the time of chemotherapy completion, and at the time of the study was 5 years (minimum-maximum: 1.7-13), 8 years (minimum-maximum: 4.25-16), and 11.7 years (minimum-maximum: 7-22), respectively, and median follow-up time was 4 years (minimum-maximum: 2-10.1). At least one complication was observed in 81.6% of patients. Vitamin D insufficiency/deficiency (46.6%), overweight/obesity (33.3%), and dyslipidemia (23.3%) were the three most frequent endocrine complications. Other complications seen in our patients were hyperparathyroidism secondary to vitamin D deficiency (15%), insulin resistance (11.7%), hypertension (8.3%), short stature (6.7%), thyroid function abnormality (5%), precocious puberty (3.3%), and decreased bone mineral density (1.7%). There were no statistically significant correlations between endocrine complications and age, sex, and radiotherapy, except vitamin D insufficiency/deficiency, which was significantly more frequent in pubertal ALL survivors compared to prepubertal ALL survivors (57.5% and 25%, respectively, p=0.011). CONCLUSION: A high frequency of endocrine complications was observed in the current study. The high frequency of late effects necessitates long-term surveillance of this population to better understand the incidence of late-occurring events and the defining of high-risk features that can facilitate developing intervention strategies for early detection and prevention.
format Online
Article
Text
id pubmed-5451687
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-54516872017-06-01 Evaluation of Endocrine Late Complications in Childhood Acute Lymphoblastic Leukemia Survivors: A Report of a Single-Center Experience and Review of the Literature Bayram, Cengiz Yaralı, Neşe Fettah, Ali Demirel, Fatma Tavil, Betül Kara, Abdurrahman Tunç, Bahattin Turk J Haematol Research Article OBJECTIVE: Improvement in long-term survival in patients with acute lymphoblastic leukemia (ALL) in childhood has led to the need for monitorization of treatment-related morbidity and mortality. In the current study, we aimed to evaluate endocrine side effects of treatment in ALL survivors who were in remission for at least 2 years. MATERIALS AND METHODS: Sixty patients diagnosed with ALL, who were in remission for at least 2 years, were cross-sectionally evaluated for long-term endocrine complications. RESULTS: The median age of the patients at the time of diagnosis, at the time of chemotherapy completion, and at the time of the study was 5 years (minimum-maximum: 1.7-13), 8 years (minimum-maximum: 4.25-16), and 11.7 years (minimum-maximum: 7-22), respectively, and median follow-up time was 4 years (minimum-maximum: 2-10.1). At least one complication was observed in 81.6% of patients. Vitamin D insufficiency/deficiency (46.6%), overweight/obesity (33.3%), and dyslipidemia (23.3%) were the three most frequent endocrine complications. Other complications seen in our patients were hyperparathyroidism secondary to vitamin D deficiency (15%), insulin resistance (11.7%), hypertension (8.3%), short stature (6.7%), thyroid function abnormality (5%), precocious puberty (3.3%), and decreased bone mineral density (1.7%). There were no statistically significant correlations between endocrine complications and age, sex, and radiotherapy, except vitamin D insufficiency/deficiency, which was significantly more frequent in pubertal ALL survivors compared to prepubertal ALL survivors (57.5% and 25%, respectively, p=0.011). CONCLUSION: A high frequency of endocrine complications was observed in the current study. The high frequency of late effects necessitates long-term surveillance of this population to better understand the incidence of late-occurring events and the defining of high-risk features that can facilitate developing intervention strategies for early detection and prevention. Galenos Publishing 2017-03 2017-03-01 /pmc/articles/PMC5451687/ /pubmed/27094350 http://dx.doi.org/10.4274/tjh.2015.0332 Text en © Copyright 2017 by Turkish Society of Hematology Turkish Journal of Hematology published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bayram, Cengiz
Yaralı, Neşe
Fettah, Ali
Demirel, Fatma
Tavil, Betül
Kara, Abdurrahman
Tunç, Bahattin
Evaluation of Endocrine Late Complications in Childhood Acute Lymphoblastic Leukemia Survivors: A Report of a Single-Center Experience and Review of the Literature
title Evaluation of Endocrine Late Complications in Childhood Acute Lymphoblastic Leukemia Survivors: A Report of a Single-Center Experience and Review of the Literature
title_full Evaluation of Endocrine Late Complications in Childhood Acute Lymphoblastic Leukemia Survivors: A Report of a Single-Center Experience and Review of the Literature
title_fullStr Evaluation of Endocrine Late Complications in Childhood Acute Lymphoblastic Leukemia Survivors: A Report of a Single-Center Experience and Review of the Literature
title_full_unstemmed Evaluation of Endocrine Late Complications in Childhood Acute Lymphoblastic Leukemia Survivors: A Report of a Single-Center Experience and Review of the Literature
title_short Evaluation of Endocrine Late Complications in Childhood Acute Lymphoblastic Leukemia Survivors: A Report of a Single-Center Experience and Review of the Literature
title_sort evaluation of endocrine late complications in childhood acute lymphoblastic leukemia survivors: a report of a single-center experience and review of the literature
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451687/
https://www.ncbi.nlm.nih.gov/pubmed/27094350
http://dx.doi.org/10.4274/tjh.2015.0332
work_keys_str_mv AT bayramcengiz evaluationofendocrinelatecomplicationsinchildhoodacutelymphoblasticleukemiasurvivorsareportofasinglecenterexperienceandreviewoftheliterature
AT yaralınese evaluationofendocrinelatecomplicationsinchildhoodacutelymphoblasticleukemiasurvivorsareportofasinglecenterexperienceandreviewoftheliterature
AT fettahali evaluationofendocrinelatecomplicationsinchildhoodacutelymphoblasticleukemiasurvivorsareportofasinglecenterexperienceandreviewoftheliterature
AT demirelfatma evaluationofendocrinelatecomplicationsinchildhoodacutelymphoblasticleukemiasurvivorsareportofasinglecenterexperienceandreviewoftheliterature
AT tavilbetul evaluationofendocrinelatecomplicationsinchildhoodacutelymphoblasticleukemiasurvivorsareportofasinglecenterexperienceandreviewoftheliterature
AT karaabdurrahman evaluationofendocrinelatecomplicationsinchildhoodacutelymphoblasticleukemiasurvivorsareportofasinglecenterexperienceandreviewoftheliterature
AT tuncbahattin evaluationofendocrinelatecomplicationsinchildhoodacutelymphoblasticleukemiasurvivorsareportofasinglecenterexperienceandreviewoftheliterature